NICE turns down Celgene’s Revlimid as multiple myeloma maintenance treatment
The drug’s cost-effectiveness estimate when used in the maintenance setting is uncertain, the Institute has concluded
Read More
Tag: Celgene
Amgen to acquire Celgene’s Otezla
The transaction is expected to close by the end of 2019.
Read More
BMS, Celgene shareholders back mega merger
The decision was won by a majority of more than 75%.
Read More
Celgene resubmits MS drug, ozanimod, to FDA
A filing for ozanimod was initially rejected by the US regulator in February 2017.
Read More
Celgene and Exscientia ink three year AI drug discovery collaboration
Exscientia has announced a three-year drug discovery AI collaboration with Celgene.
Read More
Bristol-Myers Squibb to buy Celgene
Bristol-Myers Squibb has unveiled its intent to acquire Celgene in a deal worth $74 billion, in order to “create a premier innovative biopharma company”.
Read More
Celgene walks away from Oncomed’s navicixizumab
Celgene has decided not to exercise its option to license OncoMed’s bispecific antibody navicixizumab.
Read More
Data show Imnovid-based triple therapy PFS benefit in blood cancer
Celgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone.
Read More
Celgene, Acceleron to file MDS therapy in the EU, US
Celgene and Acceleron Pharma are preparing to file their experimental myelodysplastic syndromes (MDS) therapy on both sides of the Atlantic on the back of promising data from a late-stage study.
Read More
FDA turns away filing for Celgene’s MS drug
US regulators are refusing to file Celgene’s application to market its experimental multiple sclerosis therapy ozanimod.
Read More
Cancer Research Technology links with Celgene
Cancer Research UK’s subsidiary Cancer Research Technology (CRT) has signed a five-year drug-discovery deal with Celgene to develop and commercialise new anti-cancer treatments.
Read More
Celgene pulls plug on Crohn’s disease trials
Celgene is abandoning late-stage testing of its experimental drug mongersen for Crohn’s disease after a Data Monitoring Committee concluded that it would be futile to continue.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
